BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 18710476)

  • 1. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome.
    Storr MA; Yüce B; Andrews CN; Sharkey KA
    Neurogastroenterol Motil; 2008 Aug; 20(8):857-68. PubMed ID: 18710476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids and the gastrointestinal tract.
    Massa F; Monory K
    J Endocrinol Invest; 2006; 29(3 Suppl):47-57. PubMed ID: 16751708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal endocannabinoid system: multifaceted roles in the healthy and inflamed intestine.
    Smid SD
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1383-7. PubMed ID: 18671715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pathophysiology of irritable bowel syndrome].
    Zouiten ML; Karoui S; Boubaker J; Fekih M; Mechmeche R; Filali A
    Tunis Med; 2006 May; 84(5):269-74. PubMed ID: 16915774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endocannabinoid system and gut-brain signalling.
    Storr MA; Sharkey KA
    Curr Opin Pharmacol; 2007 Dec; 7(6):575-82. PubMed ID: 17904903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: endocannabinoids and their receptors in the enteric nervous system.
    Duncan M; Davison JS; Sharkey KA
    Aliment Pharmacol Ther; 2005 Oct; 22(8):667-83. PubMed ID: 16197488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The putative role of the intestinal microbiota in the irritable bowel syndrome.
    Collins SM; Denou E; Verdu EF; Bercik P
    Dig Liver Dis; 2009 Dec; 41(12):850-3. PubMed ID: 19740713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral factors in the pathophysiology of irritable bowel syndrome.
    Gunnarsson J; Simrén M
    Dig Liver Dis; 2009 Nov; 41(11):788-93. PubMed ID: 19665956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut feelings about the endocannabinoid system.
    Di Marzo V; Piscitelli F
    Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From endocannabinoid profiling to 'endocannabinoid therapeutics'.
    Ligresti A; Petrosino S; Di Marzo V
    Curr Opin Chem Biol; 2009 Jun; 13(3):321-31. PubMed ID: 19497779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
    Konturek PC; Brzozowski T; Konturek SJ
    J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving concepts of the pathogenesis of irritable bowel syndrome: to treat the brain or the gut?
    Camilleri M
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S46-8. PubMed ID: 19300123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids and gastrointestinal motility: animal and human studies.
    Aviello G; Romano B; Izzo AA
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():81-93. PubMed ID: 18924447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome.
    Delvaux M
    Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):747-71. PubMed ID: 15324712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered protease signalling in the gut: a novel pathophysiological factor in irritable bowel syndrome.
    Róka R; Wittmann T; Bueno L
    Neurogastroenterol Motil; 2008 Aug; 20(8):853-6. PubMed ID: 18710475
    [No Abstract]   [Full Text] [Related]  

  • 16. The brain-gut axis in irritable bowel syndrome--clinical aspects.
    Mach T
    Med Sci Monit; 2004 Jun; 10(6):RA125-31. PubMed ID: 15173682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irritable bowel syndrome and bloating.
    Hasler WL
    Best Pract Res Clin Gastroenterol; 2007; 21(4):689-707. PubMed ID: 17643909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of gut hormones with irritable bowel syndrome.
    Zhang H; Yan Y; Shi R; Lin Z; Wang M; Lin L
    Digestion; 2008; 78(2-3):72-6. PubMed ID: 18948690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteric alpha-2 adrenoceptors: pathophysiological implications in functional and inflammatory bowel disorders.
    Blandizzi C
    Neurochem Int; 2007 Oct; 51(5):282-8. PubMed ID: 17618014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation.
    Camilleri M; Carlson P; McKinzie S; Grudell A; Busciglio I; Burton D; Baxter K; Ryks M; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G13-9. PubMed ID: 17962356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.